BTG Pactual Global Asset Management Ltd grew its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 17.3% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,410 shares of the biopharmaceutical company’s stock after buying an additional 652 shares during the period. BTG Pactual Global Asset Management Ltd’s holdings in Alnylam Pharmaceuticals were worth $434,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Robeco Institutional Asset Management B.V. bought a new stake in shares of Alnylam Pharmaceuticals during the first quarter valued at approximately $170,000. Mutual of America Capital Management LLC raised its holdings in shares of Alnylam Pharmaceuticals by 98.5% during the second quarter. Mutual of America Capital Management LLC now owns 1,935 shares of the biopharmaceutical company’s stock valued at $191,000 after buying an additional 960 shares during the last quarter. IPG Investment Advisors LLC bought a new stake in shares of Alnylam Pharmaceuticals during the second quarter valued at approximately $217,000. First Republic Investment Management Inc. bought a new stake in shares of Alnylam Pharmaceuticals during the second quarter valued at approximately $230,000. Finally, Riverhead Capital Management LLC raised its holdings in shares of Alnylam Pharmaceuticals by 195.6% during the second quarter. Riverhead Capital Management LLC now owns 2,365 shares of the biopharmaceutical company’s stock valued at $233,000 after buying an additional 1,565 shares during the last quarter. 93.39% of the stock is currently owned by institutional investors.
Shares of NASDAQ:ALNY opened at $112.13 on Friday. Alnylam Pharmaceuticals, Inc. has a 12 month low of $70.76 and a 12 month high of $153.99. The company has a current ratio of 13.22, a quick ratio of 13.22 and a debt-to-equity ratio of 0.02.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($1.63) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.74) by $0.11. The firm had revenue of $29.91 million for the quarter, compared to analyst estimates of $16.96 million. Alnylam Pharmaceuticals had a negative net margin of 533.52% and a negative return on equity of 38.09%. The firm’s quarterly revenue was up 87.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.07) earnings per share. analysts expect that Alnylam Pharmaceuticals, Inc. will post -7.08 earnings per share for the current fiscal year.
A number of research firms have recently weighed in on ALNY. Cowen reaffirmed a “buy” rating and set a $147.00 price target on shares of Alnylam Pharmaceuticals in a report on Tuesday. JMP Securities set a $198.00 price target on Alnylam Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, August 28th. ValuEngine raised Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Tuesday, August 28th. Needham & Company LLC set a $152.00 target price on Alnylam Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, August 27th. Finally, BidaskClub raised Alnylam Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, August 23rd. Three analysts have rated the stock with a sell rating, three have given a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $141.57.
In other Alnylam Pharmaceuticals news, SVP Laurie Keating sold 1,563 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Wednesday, June 20th. The shares were sold at an average price of $105.04, for a total value of $164,177.52. Following the transaction, the senior vice president now owns 16,063 shares in the company, valued at $1,687,257.52. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, COO Yvonne Greenstreet sold 2,500 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Thursday, August 30th. The stock was sold at an average price of $120.00, for a total transaction of $300,000.00. Following the completion of the transaction, the chief operating officer now owns 1,916 shares in the company, valued at approximately $229,920. The disclosure for this sale can be found here. In the last 90 days, insiders sold 54,063 shares of company stock worth $5,733,678. 4.30% of the stock is currently owned by company insiders.
Alnylam Pharmaceuticals Profile
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia.
Read More: Investing in Dividend Stocks
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.